HALO Dec 2024 55.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:14PM EDT. Market open.
| Previous close | 5.3700 |
| Open | 4.0000 |
| Bid | 3.2000 |
| Ask | 4.8000 |
| Strike | 55.00 |
| Expiry date | 2024-12-20 |
| Day's range | 4.0000 - 4.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksWhy This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Simply Wall St.Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
© 2024 Yahoo. All rights reserved.